Skip to Content

New Class of Medicines Emerge as Potential Therapies in MTAP-Deleted NSCLC

In this MEDtalk from the World Conference on Lung Cancer (WCLC), Dr. Pasi A. Jänne, MD, PhD, Senior Vice President of Translational Medicine at Dana-Farber Cancer Institute, presents promising phase 1 results for the PRMT5 inhibitor BMS-986504 in MTAP-deleted non-small cell lung cancer. The agent shows durable responses and good tolerability, including in patients with EGFR and ALK-positive tumors who have received prior targeted therapies.

Pasi Jänne

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top